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Class IIa histone deacetylases (HDACs) repress genes involved in pathological cardiac hypertrophy.
The anti-hypertrophic action of class IIa HDACs is overcome by signals that promote their phosphor-
ylation-dependent nuclear export. Several kinases have been shown to phosphorylate class IIa
HDACs, including calcium/calmodulin-dependent protein kinase (CaMK), protein kinase D (PKD)
and G protein-coupled receptor kinase (GRK). However, the identity of the kinase(s) responsible
for phosphorylating class IIa HDACs during cardiac hypertrophy has remained controversial. We
describe a novel and selective small molecule inhibitor of PKD, bipyridyl PKD inhibitor (BPKDi).
BPKDi blocks signal-dependent phosphorylation and nuclear export of class IIa HDACs in cardio-
myocytes and concomitantly suppresses hypertrophy of these cells. These studies deﬁne PKD as a
principal cardiac class IIa HDAC kinase.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Pathological cardiac hypertrophy is accompanied by diverse
alterations in myocyte gene expression. For example, stress signal-
ing in the adult heart results in up-regulation of dormant ‘‘fetal
cardiac genes” encoding embryonic isoforms of proteins that gov-
ern growth, contractility, calcium handling and energetics, with
concomitant down-regulation of the adult isoforms [1,2]. This gene
reprogramming is contingent on phosphorylation-dependent nu-
clear export of class IIa histone deacetylases (HDACs), which func-
tion as endogenous repressors of cardiac gene expression [3].
Intense investigation has focused on identiﬁcation of class IIa
HDAC kinases. Over 500 genes in the human genome encode ki-
nases, and this ‘‘kinome” is comprised of seven superfamilies [4].
Molecular, biochemical and pharmacological investigations have
led to the identiﬁcation of three families of class IIa HDAC kinases:
Ca2+/calmodulin-dependent protein kinase II (CaMKII), protein ki-
nase D (PKD) and microtubule afﬁnity-regulating kinase (MARK),
all of which possess related catalytic domains and fall within the
CaMK superfamily [5,6]. More recently, salt-inducible kinasechemical Societies. Published by E
. McKinsey).
(L. Monovich), timothy.mck-(SIK) [7], which is also a member of the CaMK superfamily, and
G protein- coupled receptor kinase 5 (GRK5) [8], a member of
the the unrelated AGC kinase superfamily, have been described
as class IIa HDAC kinases.
Using high throughput screening and medicinal chemistry, we
have identiﬁed a series of selective small molecule inhibitors of
PKD. We describe the in vitro and cellular activity of one of these
compounds, which we refer to here as bipyridyl PKD inhibitor
(BPKDi). BPKDi inhibits the three members of the PKD family,
PKD1, PKD2 and PKD3, with IC50 values of 1 nM, 9 nM and 1 nM,
respectively. In contrast, the compound fails to signiﬁcantly inhibit
other putative class IIa HDAC kinases. In cultured cardiac
myocytes, BPKDi blocks agonist-dependent PKD activation and
phosphorylation-dependent nuclear export of class IIa HDACs -4
and -5. Pharmacological inhibition of PKD activity is associated
with attenuation of myocyte hypertrophy. These studies establish
a key role for PKD in cardiomyocyte signaling and gene regulation.
2. Methods
2.1. PKD1 enzymatic assay
The assay to measure protein kinase D1 (PKD1) activity was a
time-resolved ﬂuorescence resonance transfer (TR-FRET) assaylsevier B.V. All rights reserved.
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human PKD1 was expressed and puriﬁed from Sf9 insect cells. Bio-
tinylated syntide-2 peptide was used as the substrate. The reaction
buffer consisted of Tris–HCl (35 mM; pH 7.5), MgCl2 (5 mM),
Tween-20 (0.02%), ATP (20 lM), DTT (1 mM) and PKD1 (0.2 lg/
ml) enzyme. Reactions were initiated by the addition of syntide-
2 peptide (2 lM) and carried out for 50 min at room temperature.
Reactions were stopped by a stop/detection buffer consisting of
EDTA (50 mM), rabbit polyclonal anti-phospho syntide-2 antibody
(0.18 mg/ml), europium (Eu)-labeled anti-rabbit IgG (0.5 nM) and
streptavidin-conjugated allophycocyanin (APC; 10 nM). After 1 h
of incubation at room temperature, FRET signal was read using
an Envision 2100 Reader and the LANCE™ Eu/APC dual protocol
(Perkin–Elmer). Additional details of the screen and medicinal
chemistry follow-up will be described elsewhere. Kinase selectiv-
ity testing was performed by Invitrogen (SelectscreenTM) using
the indicated recombinant kinases.
2.2. NRVM preparation, culture and stimulation
Hearts were dissected from 1 to 3 day-old Sprague–Dawley rats,
minced, and digested with collagenase (Worthington; 600 lg/ml)
and pancreatin (Sigma; 1X activity equivalent) in 1 Ads buffer
(NaCl [116 mM], HEPES [20 mM; pH 7.4], NaH2PO4 [4.8 mM], KCl
[5 mM], MgSO4 [400 lM], and glucose [5.5 mM]). Cells were cen-
trifuged through a step gradient of Percoll (Pharmacia) to separate
myocytes from ﬁbroblasts, and the myocyte pool was further en-
riched by pre-plating for 2 h to remove adherent ﬁbroblasts from
the cell population. Cells were plated on gelatin-coated plates in
DMEM containing FBS (10%), penicillin–streptomycin and L-gluta-
mine (DMEM complete). After 12 h, plating medium was replaced
with serum-free DMEM supplemented with Nutridoma-SP (0.1%;
Roche Applied Sciences). For studies with adenoviruses, cells were
mixed with virus (multiplicity of infection = 25) at the time of plat-
ing and washed 12 h post-plating. Cells were ﬁxed with 10% forma-
lin and washed with PBS prior to visualize of GFP-HDACs with an
inverted ﬂuorescence microscope. Adenoviruses for GFP-HDAC4
and GFP-HDAC5 have been previously described [9,10]. Phenyleph-
rine (PE) and phorbol-12-myristate-13-acetate (PMA) were pur-
chased from Sigma–Aldrich and endothelin-1 (ET-1) from
Phoenix Pharmaceuticals.
2.3. Immunoblotting and immunoprecipitation
NRVMs were lysed in Tris buffer (50 mM, pH 7.5) containing
EDTA (5 mM), Triton-X100 (1%), protease and phosphatase inhibi-
tor cocktails (Thermo Scientiﬁc). Homogenates were brieﬂy soni-
cated and cleared by centrifugation. Total protein was resolved
by SDS–polyacrylamide gel electrophoresis (PAGE) with gradient
gels (4–20% polyacrylamide; Invitrogen). Proteins were transferred
to nitrocellulose membranes (Bio-Rad) and probed with one of the
following antibodies: anti-phospho-PKD serine-916 (Cell Signaling
Technology #2051), anti-phospho-PKD serines-744/748 (Cell Sig-
naling Technology #2054), anti-total PKD (Cell Signaling Technol-
ogy #2052), anti-phospho-HDAC5 serine-259 (cross-reacts with
phospho-HDAC4 serine-246) [11], anti-phospho-HDAC5 serine-
498 (cross-reacts with phospho-HDAC4 serine-467) (Abcam
#47283). All antibody incubations were performed with 1:500
dilutions of antibody in TBS-T containing 3% BSA, overnight at
4 C with rocking. Secondary HRP-conjugated anti-rabbit antibody
was purchased from Southern Biotechnology. Proteins were visual-
ized using a chemiluminescence system (Thermo Scientiﬁc, Super-
Signal West Pico system). For immunoprecipitation experiments,
ﬁve 10-cm plates of NRVMs (1.8  106 cells/plate) were used per
experimental condition. Lysates were prepared as described for
immunoblotting and subjected to rabbit anti-serum againstHDAC4 or HDAC5 [12] or control pre-immune serum and Exacta
Cruz beads (Santa Cruz Biotechnology; 10 ll packed volume).
Immunoprecipitation was conducted overnight at 4 C with rock-
ing and beads were subsequently washed ﬁve times in lysis buffer
and prepared for SDS–PAGE.
2.4. Hypertrophy and toxicity measurements
Myomaxin, alpha-skeletal actin (a-Sk-actin), b-myosin heavy
chain (b-MyHC), and atrial natriuretic factor (ANF) mRNA
expression was quantiﬁed from NRVM lysates using the branched-
DNA-technology-based QuantiGene Reagent System (Panomics,
Fremont CA), according to the manufacturer’s protocols. Three-
dimensional measurements of NRVMs were conducted using a
Coulter Model Z2 instrument (Beckman), as previously described
[9]. Brieﬂy, cells in 6-well dishes (2.5  105 cells/well) were
washed 1 with PBS and trypsinized (200 ll trypsin; 2 min at
room temperature). DMEM containing 10% FBS (2 ml) was added
to trypsinized cells and cells were dispersed by vigorous pipetting.
Cells were washed 1 with PBS and transferred to cuvettes con-
taining Isoﬂow buffer (Coulter; 10 ml). Volume measurements
were obtained for 1  104 cells with Coulter aperture diameter
limits between 6 and 26 lm. Cell volumes are expressed as lm3.
Adenylate kinase (AK) was measured in culture supernatants
employing the bioluminescent ToxiLight kit (Cambrex) according
to the manufacturer’s instructions.3. Results
3.1. Identiﬁcation of BPKDi, a selective inhibitor of PKD
High-throughput screening was performed to identify small
molecule inhibitors of recombinant protein kinase D1 (PKD1). A li-
brary of >650 000 compounds was screened using a time-resolved
ﬂuorescence resonance transfer (TR-FRET) assay (Perkin–Elmer’s
LANCE™) to measure activity of full-length, human PKD1 overex-
pressed in insect cells, as described in Section 2. The substrate
for PKD1 was a biotinylated syntide-2 peptide. Medicinal chemis-
try and structure–activity-relationship (SAR) studies yielded an
amido bipyridyl analog of a hit compound, termed BPKDi
(Fig. 1A), which potently inhibited PKD1, as well as PKD2 and
PKD3 (Table 1). Further details of the discovery of this novel PKD
inhibitor will be described elsewhere.
BPKDi was tested for its ability to inhibit other putative class IIa
HDAC kinases in vitro using the Invitrogen Selectscreen service. As
shown in Table 1, the compound failed to inhibit members of the
CaMKII and MARK families, and also lacked the ability to signiﬁ-
cantly inhibit SIK1 and GRK5 at the 1 lM screening concentration.
In contrast, dose–response studies revealed that BPKDi inhibited
recombinant forms of each of the three PKD isoforms with low
nanomolar potency. The activity of BPKDi against the entire Invit-
rogen panel of over 250 kinases will be described elsewhere.
3.2. BPKDi selectively blocks cellular PKD activity
Protein kinase C (PKC)-mediated phosphorylation of activation
loop serines on PKD1 results in PKD1 activation, as evidenced by
auto-phosphorylation of PKD1 [13,14]. To determine whether
BPKDi blocks endogenous, cellular PKD1 activity, neonatal rat ven-
tricular myocytes (NRVMs) were pre-treated with compound and
then stimulated with the PKC activator, phorbol myristate acetate
(PMA). As shown in Fig. 1B, BPKDi signiﬁcantly attenuated PMA-in-
duced auto-phosphorylation of PKD1 on serine-916. Importantly,
BPKDi had no effect on PKC-mediated phosphorylation of the
PKD1 activation loop serines 744/748, illustrating the cellular
Fig. 1. BPKDi inhibits endogenous PKD1 signaling in cardiac myocytes. (A) Structure of BPKDi. (B) Neonatal rat ventricular myocytes (NRVMs; 2  106 cells/10-cm plate) were
cultured in serum-free medium and incubated in the absence or presence of BPKDi (1 lM) for 30 min prior to exposure to PMA (25 nM) for 1 h, as indicated. Total protein was
prepared and analyzed by immunoblotting with an antibody that recognizes PKD1 when auto-phosphorylated on serine-916 (upper panel), an antibody that recognizes PKD1
when phosphorylated by PKC on serines-744 and 748 (middle panel), or an antibody to total PKD1 (lower panel) to control for protein loading. (C) NRVMs were treated as
described in (B) and stimulated for 1 h with ET-1 (25 nM), PGF2a (10 lM) or PE (10 lM) prior to protein lysate preparation and immunoblotting. Each experiment shown in
this ﬁgure was performed with NRVMs prepared on separate days.
Table 1
BPKDi speciﬁcally inhibits PKD family members. BPKDi (1 lM) was tested for its
ability to block activity the indicated recombinant kinases. IC50 values were
determined for PKD1, PKD2 and PKD3. Kinase assays were performed by Invitrogen.
n.d., not determined.
Kinase % Inhibition at 1 lM BPKDi IC50 (lM)
PKD1 102 0.001
PKD2 102 0.009
PKD3 109 0.001
CaMKId 6 n.d.
CaMKIIa 0 n.d.
CaMKIIb 3 n.d.
CaMKIId 26 n.d.
CaMKIV 1 n.d.
MARK1 24 n.d.
MARK2 27 n.d.
SIK1 7 n.d.
GRK5 2 n.d.
PKCd 22 n.d.
PKCe 3 n.d.
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PKD1 auto-phosphorylation in response to three independent G
protein-coupled receptor (GPCR) agonists, endothelin-1 (ET-1),
prostaglandin-F2a (PGF2a) and phenylephrine (PE) (Fig. 1C). The
antibody against phospho-serine-916 cross-reacts with PKD2, but
PKD3 lacks an equivalent site. Prior siRNA studies demonstrated
that PKD1-specﬁc knockdown in NRVMs abolished antibody reac-tivity [15], and thus the immunoblots shown here reﬂect effects of
BPKDi speciﬁcally on PKD1 auto-phosphorylation.3.3. Endogenous PKD regulates phosphorylation of class IIa HDACs
Serines-259 and -498 are the primary phospho-acceptors that
control nuclear export of human HDAC5 [12,16]. The equivalent
sites in human HDAC4 are serines-246 and -467. Upon phosphor-
ylation, these sites are bound by the 14-3-3 chaperone protein
[16–18], which exposes a cryptic nuclear export sequence in class
IIa HDACs. BPKDi was employed to determine the role of PKD in
the regulation of HDAC4/5 phosphorylation in cardiac myocytes.
Initial studies were performed by overexpressing GFP-tagged
HDAC4 or HDAC5 in NRVMs using adenoviruses. Cells were pre-
treated with vehicle or BPKDi and subsequently stimulated with
either PE or ET-1. As shown in Fig. 2A, agonist-dependent phos-
phorylation of HDAC5 was signiﬁcantly attenuated by BPKDi. Sim-
ilar results were obtained with HDAC4 (Fig. 2B).
Sequential immunoprecipitation and immunoblotting was per-
formed with lysates from uninfected NRVMs to speciﬁcally evalu-
ate the phosphorylation state of endogenous HDAC4 and HDAC5 in
response to PE in the absence and presence of BPKDi. As shown in
Fig. 2C, PE-mediated phosphorylation of both HDAC4 and HDAC5
was attenuated by BPKDi. Since the compound does not affect
the activity of other putative class IIa HDAC kinases, these results
support a role for PKD as a dominant class IIa HDAC kinase in car-
diac myocytes.
Fig. 2. BPKDi blocks agonist-dependent phosphorylation of HDAC4 and HDAC5. (A) NRVMs (2  106/10-cm plate) were infected with adenovirus encoding GFP-tagged
HDAC5. After 14 h of infection, cells were washed and cultured in serum-free medium. Cells were exposed to BPKDi (1 lM) for 30 min prior to stimulation for 1 h with either
PE (10 lM) or ET-1 (25 nM), as indicated. Total protein was prepared and analyzed by immunoblotting with an antibody that recognizes HDAC5 when phosphorylated on
serine-259 (upper panel), an antibody that recognizes HDAC5 when phosphorylated on serine-498 (middle panel), or an antibody to GFP (lower panel) to control for protein
loading. (B) NRVMs (2  106 cells/10-cm plate) were infected with adenovirus encoding GFP-tagged HDAC4. Cells were treated with BPKDi (1 lM) and agonists as described
in (A), and immunoblotting was performed to assess HDAC4 phosphorylation. Note that HDAC4 is basally phosphorylated. The reduced phospho-signals seen in lane two
(upper and middle panels) appear to be a consequence of lower total HDAC4 loading (bottom panel). (C) Uninfected NRVMs were cultured in serum-free medium in the
absence or presence of BPKDi (1 lM) and stimulated for 1 h with PE (20 lM), as indicated. Total protein lysates were immunoprecipitated (IP) with antibody to either HDAC5
(left-hand panels) or HDAC4 (middle panels). Immunoprecipitates were split in two and run on separate gels for immunoblotting (IB) with either anti-phospho-HDAC
antibody (upper panels) or total HDAC antibody (lower panels). Separate immunoprecipitations were performed with normal rabbit serum as a negative control for non-
speciﬁc pulldown (right-hand panels).
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myocytes
Fluorescence microscopy was used to determine if PKD regu-
lates phosphorylation-dependent nuclear export of class IIa HDACs
in NRVMs. Cells were infected with adenoviruses encoding GFP-
tagged forms on HDAC4 or HDAC5. HDAC5 was predominantly nu-
clear in unstimulated NRVMs but rapidly relocated to the cyto-
plasm in response to PMA, PE or ET-1 treatment (Fig. 3A, upper
panels). BPKDi completely blocked agonist-dependent nuclear ex-
port of HDAC5 (Fig. 3A, lower panels).
GFP-HDAC4was primarily localized to nuclei of infected NRVMs,
although some cytoplasmic and pan-cellular distribution was
noted. In response to PMA, PE and ET-1, HDAC4 efﬁciently redistrib-
uted to the cytoplasm (Fig. 3B, upper panels). However, HDAC4 re-
mained nuclear in agonist-stimulated cells pre-treated with BPKDi
(Fig. 3B, lower panels). BPKDi had onlymarginal effects on basal nu-
clear export of HDAC4 (data not shown), suggesting that basal phos-
phorylation of HDAC4 is regulated by a kinase distinct from PKD.
Alternatively, the 1 h duration of compound treatment was not suf-
ﬁcient to allow de-phosphorylation of HDAC4. Despite this uncer-tainty, the results support a role for PKD in the control of agonist-
dependent phosphorylation of HDACs 4 and 5 in cardiac myocytes.
3.5. BPKDi blunts pathologic cardiac gene expression and myocyte
hypertrophy
Class IIa HDACs associate with MEF2 transcription factors and
thereby repress target genes harboring MEF2 binding sites. BPKDi
was used to determine the role of endogenous PKD in the control
of the cardiac-speciﬁc MEF2 target gene, myomaxin [19]. NRVMs
were exposed to the hypertrophic agonist PE in the absence or
presence of BPKDi for 72 h. As shown in Fig. 4A, BPKDi completely
blocked agonist-dependent induction of myomaxin mRNA expres-
sion, supporting the notion that PKD derepresses MEF2 target
genes via class IIa HDACs.
BPKDi was employed to examine the contribution of PKD sig-
naling to activation of additional hypertrophic marker genes,
including those encoding atrial natriuretic factor (ANF), b-myosin
heavy chain (b-MyHC) and a-skeletal actin (a-Sk-actin). As shown
in Fig. 4B and C, BPKDi completely blocked PE-mediated induction
a-Sk-actin and b-MyHC mRNA expression. In contrast, ANF expres-
Fig. 3. BPKDi blocks agonist-dependent nuclear export of HDAC4 and HDAC5. NRVMs were cultured in 6-well plates (2  105 cells/well) and infected with adenovirus
encoding GFP-tagged HDAC5 (A) or GFP-tagged HDAC4 (B). After 14 h of infection, cells were washed and cultured in serum-free medium. Cells were exposed to BPKDi (1 lM)
for 30 min prior to stimulation with PMA (25 nM), PE (10 lM) or ET-1 (25 nM) for 1 h. GFP-HDAC was visualized using a ﬂuorescence microscope. Scale bar = 10 lm.
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combination of BPKDi and PE (Fig. 4D). These results suggest that
PKD signaling does not serve a general role in cardiac gene regula-
tion, but instead selectively functions to control a subset of genes
that are induced during cardiac hypertrophy.
To more directly examine the effect of PKD inhibition on cardiac
hypertrophy, the ability of BPKDi to alter NRVM growth was as-
sessed. Seventy two hours of stimulation with PE caused a 21% in-
crease in NRVM cell volume that was blunted by 40% by BPKDi
(Fig. 4E). Adenylate kinase (AK), which is released from cells when
plasma membrane integrity is compromised, was measured in the
culture supernatants to access possible cytotoxic effects of BPKDi
on NRVMs. Importantly, the addition of 1 lM BPKDi to NRVMs for
72 h did not promote AK release from cells (data not shown), and
thus the results reﬂect authentic anti-hypertrophic activity of the
compound rather than non-speciﬁc toxicity. Additional studies of
AK release demonstrated that 10 lM BPKDi was well tolerated by
NRVMs exposed to the compound for 72 h. BPKDi was also non-
toxic to cultured adult rat ventricular myocytes (data not shown).
4. Discussion
Signal-dependent nuclear export of class IIa HDACs is required
for derepression of genes that promote cardiomyocyte hypertro-phy. Here, using a novel and highly selective kinase inhibitor, we
provide evidence that PKD plays a critical role in this process by di-
rectly phosphorylating class IIa HDACs in response to GPCR
agonists.
Prior genetic studies have implicated PKD in the control of class
IIa HDAC phosphorylation and cardiac hypertrophy. Overexpres-
sion of constitutively active forms of PKD triggers nuclear export
of class IIa HDACs [11,20,21]. Conversely, siRNA knockdown of
PKD1 in NRVMs blunts hypertrophy and nuclear export of HDAC5
[15]. Transgenic overexpression of active PKD1 in mouse heart
causes pathological cardiac remodeling [11], while cardiac-speciﬁc
knockout of the gene encoding PKD1 blunts hypertrophy in re-
sponse to pressure overload [22]. Our studies with BPKDi further
implicate PKD in the control of cardiac hypertrophy via class IIa
HDACs. Future in vivo studies with this compound or analogs
should establish the relative importance of PKD signaling to path-
ological remodeling of the heart under various conditions.
Another small molecule inhibitor of PKD, Gö-6976 [23], has
been widely used to assess the contribution of PKD to various
processes, including class IIa HDAC nuclear export [11]. However,
Gö-6976 has been shown to inhibit a variety of kinases in addition
to PKD [24], including PKC, p70 ribosomal S6 kinase, checkpoint
kinase-2 and 30-phosphoinositide-dependent protein kinase-1,
and thus results obtained with this compound are equivocal.
Fig. 4. Effect of BPKDi on cultured cardiac myocyte gene expression and hypertrophy. (A–D) NRVMs (2  106 cells/10-cm plate) were cultured in serum-free medium. Cells
were stimulated for 72 h with PE (20 lM) in the absence or presence of BPKDi (1 lM), as indicated. Total RNA was prepared and mRNA transcripts for the indicated genes
were quantiﬁed as described in Section 2. Values represent averages from three independent plates of cells ± standard deviation. Statistical signiﬁcance was assessed using 1-
way ANOVA with Newman–Keuls post-test. (E) NRVMs were cultured in 6-wells dishes (2  105 cells/well) and treated for 72 h as described above. Cell volume (lm3) was
quantiﬁed using a Coulter Model Z2 instrument. Values represent averages from six independent wells of cells ± standard deviation. Statistical signiﬁcance was assessed
using 1-way ANOVA with Newman–Keuls post-test.
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inhibitor, CID755673, was described [25]. Unlike BPKDi, which is
an ATP-competitive PKD inhibitor (data not shown), CID755673-
mediated inhibition of PKD is non-competitive with respect to
ATP. The degree of selectivity of CID755673 for PKD, and thus
the speciﬁcity of the compound, has recently been questioned [26].
BPKDi does not distinguish between PKD1, PKD2 and PKD3.
Prior gene targeting studies in chicken B lymphocytes demon-
strated that PKD1 and PKD3 function redundantly to control
HDAC5 phosphorylation in these cells [27]. Additionally, siRNAknockdown of PKD1 in NRVMs only partially prevented HDAC5 nu-
clear export [15], further suggesting that multiple PKD family
members control class IIa HDAC phosphorylation. The profound ef-
fect of BPKDi on class IIa HDAC phosphorylation and nuclear export
is likely due to its ability to inhibit all PKD family members. How-
ever, it is important to note that the immunoblotting results shown
in Fig. 1 only capture the activation state of PKD1.
CaMKII has been strongly associated with HDAC4 regulation in
the heart [28]. HDAC4 harbors a unique CaMKII docking domain
not found in other class IIa HDACs. BPKDi does not inhibit CaMKII,
L. Monovich et al. / FEBS Letters 584 (2010) 631–637 637yet it efﬁciently prevented phosphorylation and nuclear export of
HDAC4 in NRVMs treated with PE and ET-1. It is possible that
HDAC4 is regulated by multiple kinases in cardiac myocytes, and
that the operative kinase is dependent on the nature of activating
stimulus. The same possibility exists for HDAC5, which is capable
of being phosphorylated by GRK5 in cardiac myocytes [8]. None-
theless, the results presented here demonstrate that in NRVMs
treated with agonists that stimulate Gaq-coupled receptors, PKD
is likely the principal kinase for HDAC4 and HDAC5.
Our ﬁndings solidify a role for PKD in cardiomyocyte signal
transduction through effects on class IIa HDACs. Prior genetic stud-
ies have also suggested that PKD regulates cardiac contractility
through phosphorylation of troponin I [29], and PKD isoforms have
been implicated in a wide variety of additional biochemical and
biological pathways, including regulation of NF-jB and MAP kinase
signaling, cell proliferation, apoptosis, motility and Golgi transport
[30]. BPKDi is a powerful chemical tool that will enable conﬁrma-
tion or reﬁnement of the role(s) of PKD signaling in these pro-
cesses, and will undoubtedly uncover previously unrecognized
functions for the PKD family.
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